相似文献
1
Correction: Elucidating the role of N‑myristoylation in the excessive membrane localization of PD‑L1 in hypoxic cancers and developing a novel NMT1 inhibitor for combination with immune checkpoint blockade therapy.
J Exp Clin Cancer Res. 2025 Sep 4;44(1):266. doi: 10.1186/s13046-025-03533-1.
2
Elucidating the role of N-myristoylation in the excessive membrane localization of PD-L1 in hypoxic cancers and developing a novel NMT1 inhibitor for combination with immune checkpoint blockade therapy.
J Exp Clin Cancer Res. 2025 Jul 2;44(1):181. doi: 10.1186/s13046-025-03438-z.
3
Impact of PD‑L1 upregulation on immune checkpoint inhibitor efficacy in triple‑negative breast cancer using a 4T1 murine model.
Int J Oncol. 2025 Jul;67(1). doi: 10.3892/ijo.2025.5760. Epub 2025 Jun 13.
4
Anti-CTLA4 Therapy Leads to Early Expansion of a Peripheral Th17 Population and Induction of Th1 Cytokines.
Cancer Immunol Res. 2025 Jun 4;13(6):836-846. doi: 10.1158/2326-6066.CIR-24-1055.
5
Tumour-intrinsic PDL1 signals regulate the Chk2 DNA damage response in cancer cells and mediate resistance to Chk1 inhibitors.
Mol Cancer. 2024 Oct 30;23(1):242. doi: 10.1186/s12943-024-02147-z.
6
ANV600 is a novel PD-1 targeted IL-2Rβγ agonist that selectively expands tumor antigen-specific T cells and potentiates PD-1 checkpoint inhibitor therapy.
J Immunother Cancer. 2025 Jul 15;13(7):e011905. doi: 10.1136/jitc-2025-011905.
7
Oncolytic reovirus enhances the effect of CEA immunotherapy when combined with PD1-PDL1 inhibitor in a colorectal cancer model.
Immunotherapy. 2025 Apr;17(6):425-435. doi: 10.1080/1750743X.2025.2501926. Epub 2025 May 12.
8
Checkpoint antibody receptor modified ARMed CAR T circumvents the suppressive immunome in GBM.
Front Immunol. 2025 Jul 31;16:1579925. doi: 10.3389/fimmu.2025.1579925. eCollection 2025.
9
Acquired resistance to immune checkpoint therapy is caused by glycoprotein non-metastatic melanoma protein B signal cascade.
Commun Med (Lond). 2025 Mar 20;5(1):79. doi: 10.1038/s43856-025-00786-x.
10
Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature review.
Cancer Treat Rev. 2024 Jan;122:102652. doi: 10.1016/j.ctrv.2023.102652. Epub 2023 Nov 4.
本文引用的文献
1
Elucidating the role of N-myristoylation in the excessive membrane localization of PD-L1 in hypoxic cancers and developing a novel NMT1 inhibitor for combination with immune checkpoint blockade therapy.
J Exp Clin Cancer Res. 2025 Jul 2;44(1):181. doi: 10.1186/s13046-025-03438-z.
Zotero 插件